{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:56:53Z","timestamp":1781650613440,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16983"],"award-info":[{"award-number":["19K16983"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K09671"],"award-info":[{"award-number":["23K09671"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49025-w","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:56:29Z","timestamp":1776707789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sodium\u2013glucose cotransporter 2 inhibitor ameliorates podocyte hypertrophic stress by suppressing the mTOR\/p70S6K\/cyclin D1 signaling pathway in obesity-related nephropathy"],"prefix":"10.1038","volume":"16","author":[{"given":"Miho","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kurimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"49025_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2017","unstructured":"Bikbov, B. et al. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study. Lancet 395, 709\u2013733 (2017).","journal-title":"Lancet"},{"key":"49025_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.ki.5002586","volume":"73","author":"Y Wang","year":"2008","unstructured":"Wang, Y., Chen, X., Song, Y., Caballero, B. & Cheskin, L. J. Association between obesity and kidney disease: A systematic review and meta-analysis. Kidney Int. 73, 19\u201333 (2008).","journal-title":"Kidney Int."},{"key":"49025_CR3","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1046\/j.1523-1755.2001.0590041498.x","volume":"59","author":"N Kambham","year":"2001","unstructured":"Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J. & D\u2019Agati, V. D. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int. 59, 1498\u20131509 (2001).","journal-title":"Kidney Int."},{"key":"49025_CR4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NH Phelps","year":"2024","unstructured":"Phelps, N. H. et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403, 1027\u20131050 (2024).","journal-title":"Lancet"},{"key":"49025_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","volume":"144","author":"CY Hsu","year":"2006","unstructured":"Hsu, C. Y., McCulloch, C. E., Iribarren, C., Darbinian, J. & Go, A. S. Body mass index and risk for end stage renal disease. Ann. Intern. Med. 144, 21\u201328 (2006).","journal-title":"Ann. Intern. Med."},{"key":"49025_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1681\/ASN.2005060638","volume":"17","author":"E Ejerblad","year":"2006","unstructured":"Ejerblad, E. et al. Obesity and risk for chronic renal failure. J. Am. Soc. Nephrol. 17, 1695\u20131702 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"49025_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000499486","volume":"143","author":"A Chagnac","year":"2019","unstructured":"Chagnac, A., Zingerman, B., Rozen-Zvi, B. & Herman-Edelstein, M. Consequences of glomerular hyperfiltration: The role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity. Nephron 143, 38\u201342 (2019).","journal-title":"Nephron"},{"key":"49025_CR8","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1093\/ndt\/gfn379","volume":"23","author":"A Chagnac","year":"2008","unstructured":"Chagnac, A. et al. Obesity-induced glomerular hyperfiltration: Its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol. Dial. Transplant. 23, 3946\u20133952 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"49025_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.111.173195","volume":"59","author":"Y Fu","year":"2012","unstructured":"Fu, Y. et al. Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors. Hypertension 59, 599\u2013606 (2012).","journal-title":"Hypertension"},{"key":"49025_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1161\/01.HYP.0000105624.68174.00","volume":"43","author":"RB De Paula","year":"2004","unstructured":"De Paula, R. B., Da Silva, A. A. & Hall, J. E. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 43, 41\u201347 (2004).","journal-title":"Hypertension"},{"key":"49025_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semnephrol.2012.12.002","volume":"33","author":"C R\u00fcster","year":"2013","unstructured":"R\u00fcster, C. & Wolf, G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin. Nephrol. 33, 44\u201353 (2013).","journal-title":"Semin. Nephrol."},{"key":"49025_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1053\/j.ackd.2014.12.004","volume":"22","author":"A Rao","year":"2015","unstructured":"Rao, A., Pandya, V. & Whaley-Connell, A. Obesity and insulin resistance in resistant hypertension: Implications for the kidney. Adv. Chronic Kidney Dis. 22, 211\u2013217 (2015).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"49025_CR13","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1681\/ASN.2006080916","volume":"17","author":"SG De Vinuesa","year":"2006","unstructured":"De Vinuesa, S. G. et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: Effects of angiotensin II blockade. J. Am. Soc. Nephrol. 17, S206\u2013S212 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"49025_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1159\/000478869","volume":"42","author":"H Wang","year":"2017","unstructured":"Wang, H., Li, J., Gai, Z., Kullak-Ublick, G. A. & Liu, Z. TNF-\u03b1 deficiency prevents renal inflammation and oxidative stress in obese mice. Kidney Blood Press. Res. 42, 416\u2013427 (2017).","journal-title":"Kidney Blood Press. Res."},{"key":"49025_CR15","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ndt\/gfs440","volume":"28","author":"K Gotoh","year":"2013","unstructured":"Gotoh, K. et al. Obesity-related chronic kidney disease is associated with spleen-derived IL-10. Nephrol. Dial. Transplant. 28, 1120\u20131130 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"49025_CR16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","volume":"320","author":"JF Moorhead","year":"1982","unstructured":"Moorhead, J. F., El-Nahas, M., Chan, M. K. & Varghese, Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 320, 1309\u20131311 (1982).","journal-title":"Lancet"},{"key":"49025_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S2213-8587(14)70065-8","volume":"2","author":"APJ De Vries","year":"2014","unstructured":"De Vries, A. P. J. et al. Fatty kidney: Emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2, 417\u2013426 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"49025_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.2215\/CJN.04071206","volume":"2","author":"IM Wahba","year":"2007","unstructured":"Wahba, I. M. & Mak, R. H. Obesity and obesity initiated metabolic syndrome: Mechanistic links to chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2, 550\u2013562 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"49025_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1681\/ASN.2007030355","volume":"19","author":"LF Ramos","year":"2008","unstructured":"Ramos, L. F., Shintani, A., Ikizler, T. A. & Himmelfarb, J. Oxidative stress and inflammation are associated with adiposity in moderate to severe ckd. J. Am. Soc. Nephrol. 19, 593\u2013599 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"49025_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrneph.2016.75","volume":"12","author":"VD D\u2019Agati","year":"2016","unstructured":"D\u2019Agati, V. D. et al. Obesity-related glomerulopathy: Clinical and pathologic characteristics and pathogenesis. Nat. Rev. Nephrol. 12, 453\u2013471 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"49025_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.semnephrol.2021.06.002","volume":"41","author":"N Tsuboi","year":"2021","unstructured":"Tsuboi, N. & Okabayashi, Y. The renal pathology of obesity: Structure-function correlations. Semin. Nephrol. 41, 296\u2013306 (2021).","journal-title":"Semin. Nephrol."},{"key":"49025_CR22","doi-asserted-by":"publisher","first-page":"F333","DOI":"10.1152\/ajprenal.00478.2012","volume":"304","author":"W Kriz","year":"2013","unstructured":"Kriz, W., Shirato, I., Nagata, M., LeHir, M. & Lemley, K. V. The podocyte\u2019s response to stress: The enigma of foot process effacement. Am. J. Physiol. Renal Physiol. 304, F333\u2013F347 (2013).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"49025_CR23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1053\/j.ajkd.2011.05.032","volume":"58","author":"JA Jefferson","year":"2011","unstructured":"Jefferson, J. A., Nelson, P. J., Najafian, B. & Shankland, S. J. Podocyte disorders: Core curriculum 2011. Am. J. Kidney Dis. 58, 666\u2013677 (2011).","journal-title":"Am. J. Kidney Dis."},{"key":"49025_CR24","doi-asserted-by":"publisher","first-page":"155718","DOI":"10.1016\/j.metabol.2023.155718","volume":"150","author":"Z Luo","year":"2024","unstructured":"Luo, Z., Chen, Z., Hu, J. & Ding, G. Interplay of lipid metabolism and inflammation in podocyte injury. Metabolism 150, 155718 (2024).","journal-title":"Metabolism"},{"key":"49025_CR25","doi-asserted-by":"publisher","first-page":"F821","DOI":"10.1152\/ajprenal.00196.2010","volume":"299","author":"J Sieber","year":"2010","unstructured":"Sieber, J. et al. Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids. Am. J. Physiol. Renal Physiol. 299, F821\u2013F829 (2010).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"49025_CR26","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/sj.ki.5002222","volume":"71","author":"R-C Wiggins","year":"2007","unstructured":"Wiggins, R.-C. The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int. 71, 1205\u20131214 (2007).","journal-title":"Kidney Int."},{"key":"49025_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54692-z","volume":"9","author":"A Minakawa","year":"2019","unstructured":"Minakawa, A. et al. Podocyte hypertrophic stress and detachment precedes hyperglycemia or albuminuria in a rat model of obesity and type 2 diabetes-associated nephropathy. Sci. Rep. 9, 18485 (2019).","journal-title":"Sci. Rep."},{"key":"49025_CR28","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"49025_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington, W. G. et al. Empagliflozin in patients with chronic kidney disease. N Engl. J. Med. 388, 117\u2013127 (2023).","journal-title":"N Engl. J. Med."},{"key":"49025_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01914-1","volume":"22","author":"X Li","year":"2024","unstructured":"Li, X. et al. Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes. Cell Commun. Signal. 22, 534 (2024).","journal-title":"Cell Commun. Signal."},{"key":"49025_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","volume":"32","author":"I Tomita","year":"2020","unstructured":"Tomita, I. et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 32, 404-419.e6 (2020).","journal-title":"Cell Metab."},{"key":"49025_CR32","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/ki.1997.335","volume":"52","author":"SJ Shankland","year":"1997","unstructured":"Shankland, S. J. Cell-cycle control and renal disease. Kidney Int. 52, 294\u2013308 (1997).","journal-title":"Kidney Int."},{"key":"49025_CR33","doi-asserted-by":"publisher","first-page":"F515","DOI":"10.1152\/ajprenal.2000.278.4.F515","volume":"278","author":"SJ Shankland","year":"2000","unstructured":"Shankland, S. J. & Wolf, G. Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation, and apoptosis. Am. J. Physiol. Renal Physiol. 278, F515\u2013F529 (2000).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"49025_CR34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/jcb.20771","volume":"98","author":"Y Jiang","year":"2006","unstructured":"Jiang, Y., Cheng, D. W., Levi, E. & Singh, L. P. IGF-1 increases laminin, cyclin D1, and P21Cip1 expression in glomerular mesangial cells: An investigation of the intracellular signaling pathway and cell-cycle progression. J. Cell. Biochem. 98, 208\u2013220 (2006).","journal-title":"J. Cell. Biochem."},{"key":"49025_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/aps.2008.8","volume":"30","author":"M Ren","year":"2009","unstructured":"Ren, M. Insulin-like growth factor-1 promotes cell cycle progression via upregulation of cyclin D1 expression through the phosphatidylinositol 3-kinase\/nuclear factor-\u03baB signaling pathway in FRTL thyroid cells. Acta. Pharmacol. Sin 30, 113\u2013119 (2009).","journal-title":"Acta. Pharmacol. Sin"},{"key":"49025_CR36","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/sj.onc.1210715","volume":"27","author":"J Averous","year":"2008","unstructured":"Averous, J., Fonseca, B. D. & Proud, C. G. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27, 1106\u20131113 (2008).","journal-title":"Oncogene"},{"key":"49025_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/ki.2014.302","volume":"87","author":"J Xu","year":"2015","unstructured":"Xu, J., Chen, J., Dong, Z., Meyuhas, O. & Chen, J.-K. Phosphorylation of ribosomal protein S6 mediates compensatory renal hypertrophy. Kidney Int 87, 543\u2013556 (2015).","journal-title":"Kidney Int"},{"key":"49025_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1525-139X.2006.00119.x","volume":"19","author":"LP Briley","year":"2006","unstructured":"Briley, L. P. & Szczech, L. A. Leptin and renal disease. Semin. Dial. 19, 54\u201359 (2006).","journal-title":"Semin. Dial."},{"key":"49025_CR39","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1161\/HYPERTENSIONAHA.116.07008","volume":"68","author":"H Li","year":"2016","unstructured":"Li, H. et al. Telmisartan ameliorates nephropathy in metabolic syndrome by reducing leptin release from perirenal adipose tissue. Hypertension 68, 478\u2013490 (2016).","journal-title":"Hypertension"},{"key":"49025_CR40","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1046\/j.1523-1755.2001.0590041315.x","volume":"59","author":"DC Han","year":"2001","unstructured":"Han, D. C. et al. Leptin stimulates type I collagen production in db\/db mesangial cells: Glucose uptake and TGF-\u03b2 type II receptor expression. Kidney Int 59, 1315\u20131323 (2001).","journal-title":"Kidney Int"},{"key":"49025_CR41","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1161\/ATVBAHA.107.147645","volume":"27","author":"K Ohashi","year":"2007","unstructured":"Ohashi, K. et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler. Thromb. Vasc. Biol. 27, 1910\u20131917 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"49025_CR42","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.metabol.2013.05.023","volume":"62","author":"K Meyvis","year":"2013","unstructured":"Meyvis, K., Verrijken, A., Wouters, K. & Van Gaal, L. Plasma adiponectin level is inversely correlated with albuminuria in overweight and obese nondiabetic individuals. Metabolism 62, 1570\u20131576 (2013).","journal-title":"Metabolism"},{"key":"49025_CR43","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1097\/01.ASN.0000141966.69934.21","volume":"15","author":"BE Wisse","year":"2004","unstructured":"Wisse, B. E. The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 15, 2792\u20132800 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"49025_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/en.2005-0641","volume":"147","author":"Y Wu","year":"2006","unstructured":"Wu, Y. et al. Obesity-related glomerulopathy: Insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 147, 44\u201350 (2006).","journal-title":"Endocrinology"},{"key":"49025_CR45","doi-asserted-by":"publisher","first-page":"18919","DOI":"10.1074\/jbc.M110650200","volume":"277","author":"L Sun","year":"2002","unstructured":"Sun, L., Halaihel, N., Zhang, W., Rogers, T. & Levi, M. Role of sterol regulatory element binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 277, 18919\u201318927 (2002).","journal-title":"J. Biol. Chem."},{"key":"49025_CR46","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1038\/sj.ijo.0802858","volume":"28","author":"JP Montani","year":"2004","unstructured":"Montani, J. P. et al. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int. J. Obes. 28, S58\u2013S65 (2004).","journal-title":"Int. J. Obes."},{"key":"49025_CR47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1046\/j.1523-1755.2000.00151.x","volume":"58","author":"H-C Huang","year":"2000","unstructured":"Huang, H.-C. & Preisig, P. A. G1 kinases and transforming growth factor-\u03b2; signaling are associated with a growth pattern switch in diabetes-induced renal growth. Kidney Int. 58, 162\u2013172 (2000).","journal-title":"Kidney Int."},{"key":"49025_CR48","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1101\/gad.7.5.812","volume":"7","author":"V Baldin","year":"1993","unstructured":"Baldin, V., Lukas, J., Marcote, M. J., Pagano, M. & Draetta, G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7, 812\u2013821 (1993).","journal-title":"Genes Dev."},{"key":"49025_CR49","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1046\/j.1523-1755.2002.00620.x","volume":"62","author":"B Liu","year":"2002","unstructured":"Liu, B. & Preisig, P. A. Compensatory renal hypertrophy is mediated by a cell cycle-dependent mechanism. Kidney Int. 62, 1650\u20131658 (2002).","journal-title":"Kidney Int."},{"key":"49025_CR50","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1002\/stem.492","volume":"28","author":"L Lasagni","year":"2010","unstructured":"Lasagni, L. et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells 28, 1674\u20131685 (2010).","journal-title":"Stem Cells"},{"key":"49025_CR51","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0002-9440(10)63228-2","volume":"164","author":"A Petermann","year":"2004","unstructured":"Petermann, A. et al. Differential expression of D-type cyclins in podocytes in vitro and in vivo. Am. J. Pathol. 164, 1417\u20131424 (2004).","journal-title":"Am. J. Pathol."},{"key":"49025_CR52","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1681\/ASN.2012111080","volume":"24","author":"K Yamahara","year":"2013","unstructured":"Yamahara, K. et al. Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J. Am. Soc. Nephrol. 24, 1769\u20131781 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"49025_CR53","first-page":"1284","volume":"19","author":"H Sun","year":"2019","unstructured":"Sun, H., Shao, X., He, J., Golos, M. & Shi, B. Role of the mTOR-FOXO1 pathway in obesity-associated renal tubulointerstitial inflammation. Mol. Med. Rep. 19, 1284\u20131293 (2019).","journal-title":"Mol. Med. Rep."},{"key":"49025_CR54","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1172\/JCI44774","volume":"121","author":"M G\u00f6del","year":"2011","unstructured":"G\u00f6del, M. et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J. Clin. Invest. 121, 2197\u20132209 (2011).","journal-title":"J. Clin. Invest."},{"key":"49025_CR55","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.kint.2022.02.037","volume":"102","author":"F Li","year":"2022","unstructured":"Li, F. et al. Blocking ribosomal protein S6 phosphorylation inhibits podocyte hypertrophy and focal segmental glomerulosclerosis. Kidney Int. 102, 121\u2013135 (2022).","journal-title":"Kidney Int."},{"key":"49025_CR56","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.kint.2024.01.044","volume":"105","author":"S Kume","year":"2024","unstructured":"Kume, S. & Packer, M. SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney. Kidney Int. 105, 1172\u20131176 (2024).","journal-title":"Kidney Int."},{"key":"49025_CR57","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.kint.2024.03.017","volume":"105","author":"M Nangaku","year":"2024","unstructured":"Nangaku, M. SGLT2 inhibitor: 2-way superstar in nephrology? Kidney Int. 105, 1176\u20131177 (2024).","journal-title":"Kidney Int."},{"key":"49025_CR58","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2024.05.006","volume":"106","author":"Y Wada","year":"2024","unstructured":"Wada, Y. et al. Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging. Kidney Int 106, 408\u2013418 (2024).","journal-title":"Kidney Int"},{"key":"49025_CR59","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/ard-2023-224242","volume":"82","author":"XY Zhao","year":"2023","unstructured":"Zhao, X. Y. et al. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann. Rheum. Dis. 82, 1328\u20131340 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"49025_CR60","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83353","volume":"12","author":"M Ge","year":"2023","unstructured":"Ge, M. et al. Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome. elife 12, e83353 (2023).","journal-title":"elife"},{"key":"49025_CR61","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon, V. et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 22, 104\u2013112 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"49025_CR62","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1681\/ASN.2013080835","volume":"25","author":"A Takeuchi","year":"2014","unstructured":"Takeuchi, A. et al. De novo expression of sodium-glucose cotransporter SGLT2 in Bowman\u2019s capsule coincides with replacement of parietal epithelial cell layer with proximal tubule-like epithelium. J. Am. Soc. Nephrol. 25, 1849\u20131859 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"49025_CR63","doi-asserted-by":"publisher","first-page":"19619","DOI":"10.1073\/pnas.1908706116","volume":"116","author":"PC Wilson","year":"2019","unstructured":"Wilson, P. C. et al. The single-cell transcriptomic landscape of early human diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A. 116, 19619\u201319625 (2019).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"49025_CR64","first-page":"2979","volume":"29","author":"P Cassis","year":"2018","unstructured":"Cassis, P. et al. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. J. Am. Soc. Nephrol. 29, 2979\u20132993 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"49025_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000411","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol 18, e3000411 (2020).","journal-title":"PLoS Biol"},{"key":"49025_CR66","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/ndt\/gfx047","volume":"32","author":"A Fukuda","year":"2017","unstructured":"Fukuda, A. et al. Urinary podocyte and TGF-\u03b21 mRNA as markers for disease activity and progression in anti-glomerular basement membrane nephritis. Nephrol. Dial. Transplant. 32, 1818\u20131830 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"49025_CR67","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1681\/ASN.2013080859","volume":"25","author":"M Venkatareddy","year":"2014","unstructured":"Venkatareddy, M. et al. Estimating podocyte number and density using a single histologic section. J. Am. Soc. Nephrol. 25, 1118\u20131129 (2014).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49025-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49025-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49025-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:26:25Z","timestamp":1781648785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49025-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49025"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49025-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18385"}}